DeepMed Research

Suzhou Suncadia Biopharmaceuticals Co., Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

Phase 1

Completed

Conditions: Moderate-to-Severe Plaque Psoriasis

Interventions: Drug: SHR-1314

First Posted Date: 2023-12-26

Last Posted Date: 2024-06-14

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 46

Registration Number: NCT06182384

Locations: 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China

Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Malignant Cancer

Interventions: Drug: SHR-2022 Injection

First Posted Date: 2023-11-14

Last Posted Date: 2023-11-14

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 116

Registration Number: NCT06131216

An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SHR-1826

First Posted Date: 2023-10-23

Last Posted Date: 2025-04-13

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 240

Registration Number: NCT06094556

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SHR-A2009 for injection；Adebrelimab Injection
Drug: SHR-A2009 for injection ； Almonertinib Mesilate Tablets

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 270

Registration Number: NCT06092268

Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors

Phase 1

Recruiting

Conditions: Advanced Malignant Tumor

Interventions: Drug: SHR-5495 for injection

First Posted Date: 2023-09-28

Last Posted Date: 2023-11-07

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT06059508

Locations: 🇨🇳
Shandong First Medical University Affiliated Cancer Hospital, Jinan, Shandong, China

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women

Phase 1

Recruiting

Conditions: Osteoporosis

Interventions: Drug: SHR-2017 injection
Drug: Placebo

First Posted Date: 2023-07-05

Last Posted Date: 2023-07-17

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 45

Registration Number: NCT05930704

Locations: 🇨🇳
The First Affiliated Hospital of Shandong First Medical University, Jinan, Shangdong, China

A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: SHR-A1811 for injection ; capecitabine

First Posted Date: 2023-05-06

Last Posted Date: 2023-08-01

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 116

Registration Number: NCT05845138

Locations: 🇨🇳
Wenzhou People's Hospital, Wenzhou, Zhejiang, China
🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijng, China
🇨🇳
Guangxi Medical University Affiliated Tumor Hospital & Oncology Medical College, Nanning, Guangxi, China

and more 6 locations

A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: SHR-4602 for injection

First Posted Date: 2023-04-19

Last Posted Date: 2024-06-21

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 133

Registration Number: NCT05819684

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: SHR-A1921；

First Posted Date: 2023-03-13

Last Posted Date: 2023-05-10

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT05765032

Locations: 🇨🇳
Tianjin Medical University Cancer Institute& Hospital, Tianjin, Tianjin, China

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

Phase 2

Active, not recruiting

Conditions: HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: SHR-A1811 and SHR-1701
Drug: SHR-A1811 and capecitabine
Drug: SHR-A181, SHR-1701, and capecitabine
Drug: SHR-A1811and 5-FU
Drug: SHR-A1811, SHR-1316, and capecitabine
Drug: SHR-A1811, SHR-1316, and 5-FU
Drug: SHR-A1811, SHR-1316, capecitabine,and oxaliplatin
Drug: SHR-1316 and SHR-A1811

First Posted Date: 2023-01-05

Last Posted Date: 2025-04-15

Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Target Recruit Count: 76

Registration Number: NCT05671822

Locations: 🇨🇳
Zhongshan Hospital, FuDan University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy